Navigation Links
Adeona Announces Positive Alzheimer's Subgroup Analysis that Supports Additional Clinical Study of Proprietary Zinc-Based Therapy
Date:6/2/2011

ared to the placebo patients of the same age.

These observations were supported by an age-related subgroup analysis that showed dosing-compliant patients age 70 and over (approximately the oldest three quartiles of the patients evaluable at the end of the study) demonstrated statistically significant improvements in two of the three cognitive scoring measurements in the reaZin treatment group compared to the placebo group. As presented below, in this subgroup, two of the three standard cognitive measures reached statistical significance (p < 0.05) as determined by the p-values (the average changes in cognitive scores from baseline to 6 months in the treatment group compared to the placebo group). The p-values were as follows:

  • ADAS-Cog - Alzheimer's Disease Assessment Scale - Cognitive Subscale p-value: 0.037
  • CDR-SOB - Clinical Dementia Rating Scale - Sum of Boxes p-value: 0.032
  • MMSE - Mini Mental State Examination p-value: 0.067

Based upon the apparent cognitive benefit observed in these older patients who were managed with reaZin in comparison to patients who received the matching placebo, Adeona is preparing a larger clinical study protocol to evaluate patients diagnosed with mild to moderate Alzheimer's disease who are age 70 and over. It is anticipated that the clinical study will enroll over 100 patients and that the evaluation period will be at least 12 months. The intention is to develop the Company's proprietary zinc-based tablet as a drug (in parallel with making reaZin available as a prescription medical food) and to conduct this new clinical study under an Investigational New Drug (IND) application to be filed with the Food & Drug Administration (FDA).

"The biological availability of zinc is impaired in Alzheimer's disease as evidenced by significantly lower plasma zinc levels and deficiencies of neuronal zinc activities, each of which
'/>"/>

SOURCE Adeona Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Adeona Appoints Julie A. Caudill, B.B.A., Vice President of Finance and Corporate Controller
2. Adeonas Multiple Sclerosis Clinical Trial Receives $1,594,553 Grant
3. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
4. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
5. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
6. Anesiva Announces Second Quarter 2008 Financial Results and Update
7. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
8. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
9. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
10. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
11. ThirdBiotech Announces Kemeta as Newest Sponsor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... (PRWEB) October 24, 2014 According ... Market by Data Center Types (Colocation, Enterprise, Telecom), ... Types (Tier 1, Tier 2, Tier 3, Tier ... MarketsandMarkets, defines and segments the Data Center Construction ... and forecasting of revenues. This research report also ...
(Date:10/25/2014)... SonaCare Medical, LLC, leader in minimally ... that its Board of Directors has appointed Dr. ... and member of the Board effective immediately. In ... responsibilities within the company, including further developing the ... manufacturing and finance. , Dr. Carol joined ...
(Date:10/25/2014)...  RegeneRx Biopharmaceuticals, Inc. (OTCBB: RGRX) ("the Company" or ... International Symposium on Thymosins in Health and Disease in ... "When thymosin beta 4 (TB4) linked with rhodamine (a ... in a rodent model of stroke, it was visualized ... (the functional tissue of the brain).   The leakage of ...
(Date:10/22/2014)... , Oct. 22, 2014 Research ... the "Global DNA Diagnostics Market (Product types, ... Share, Global Trends, Company Profiles, Demand, Insights, Analysis, ... 2020" report to their offering. ... (products, applications, techniques, end users and Geography) Global ...
Breaking Biology Technology:Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 2Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 3Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 4SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 2SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 3Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 3
... 28, 2011 TriLink BioTechnologies, Inc. (TriLink) and Lucigen ... signed a licensing agreement for the use of TriLink,s ... MasterMix. TriLink,s CleanAmp™ dNTPs are an innovative ... standard dNTPs in a PCR assay with CleanAmp™ dNTPs, ...
... SILVER SPRING, Md., July 28, 2011 United Therapeutics Corporation ... for the quarter ended June 30, 2011. "I,m ... quarter, as well as the very good operating results we ... Executive Officer. "We remain on track to reach our 2011 ...
... Mass., July 27, 2011 SomaLogic, Inc. ... today that they have entered into an ... specific SOMAmers as critical and unique reagents ... acid amplification and polymerase chain reaction (PCR) ...
Cached Biology Technology:TriLink BioTechnologies, Inc. Announces License Agreement with Lucigen Corporation 2United Therapeutics Corporation Reports Second Quarter 2011 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2011 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2011 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2011 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2011 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2011 Financial Results 7Agreement Between SomaLogic and New England Biolabs Enables the Use of SOMAmer Technology for the Optimization of Multiple PCR Products 2
(Date:10/16/2014)... (October 16, 2014) – Post-menopausal women experienced improvements ... hormone levels or genital bleeding, after 12 weeks ... investigational fermented soy germ-based nutritional supplement previously shown ... a new peer-reviewed pilot study reported in a ... annual scientific meeting. , "These data documented ...
(Date:10/15/2014)... , Oct. 15, 2014 Sandata ... for home and community-based care, today announced it ... implementing Sandata,s Santrax® Electronic Visit Verification™ Solution (EVV™) ... is a home health company founded in 1996 ... . The study details ...
(Date:10/15/2014)... a non-traditional biophysics textbook and it describes how life ... of discovery into biological systems and provides an understanding ... is about how our genes make proteins that control ... cells in an organism. It quantifies the principles of ... be found on both large and small scales. The ...
Breaking Biology News(10 mins):S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2Sandata Announces Case Study with Quality Care Services, Inc. 2New book about life as seen from physics 2
... NVIDIA CUDA Teaching Centre in Canada. The ... electrical and computer engineering students how to tap ... units (GPU) and use them in computationally demanding ... that enables dramatic increases in computing performance for ...
... successful initial testing of a new form of methotrexate ... nose drops rather than injected. It shows promise as a ... appears in ACS, Molecular Pharmaceutics , a bi-monthly journal. ... is difficult to treat, partly because current anticancer drugs have ...
... major risk factor for disease, much of the threat ... a cluster of risk factors related to diabetes and ... many of these risk factors. However, many people struggle ... the University of Missouri have found that people who ...
Cached Biology News:McMaster, NVIDIA establish first CUDA Teaching Centre in Canada 2Putting on the pounds after weight loss? Hit the gym to maintain health gains 2
... flexible on your protocols, easy on your budget. ... sample throughput instrument at a highly affordable price. ... The truly user-friendly fully interchangeable block system allows ... seconds without the need of any tools (60 ...
Preparation Note: by a modification of the procedure of C.W. Hancher et al., Biotechnol. Bioeng. 11, 1055 (1969) Assay: ~ 20 A 260 /mg Solubility: water 10 mg/mL, clear, light-yellow Suitab tst...
A collection of 42 spots with normal tissues from different organs of C57 mice, rat and human....
... The Fujifilm Life Science FLA-7000 excels ... silver-stained, CBB-stained gel documentation. It features four ... R710, and a filter for Imaging Plates) ... offers a customizable choice of four kinds ...
Biology Products: